CN106716127B - 用于检测卵巢癌的方法 - Google Patents

用于检测卵巢癌的方法 Download PDF

Info

Publication number
CN106716127B
CN106716127B CN201580052938.0A CN201580052938A CN106716127B CN 106716127 B CN106716127 B CN 106716127B CN 201580052938 A CN201580052938 A CN 201580052938A CN 106716127 B CN106716127 B CN 106716127B
Authority
CN
China
Prior art keywords
small molecule
acid
concentration
ovarian cancer
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580052938.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN106716127A (zh
Inventor
米卡·希尔沃
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zora Biosciences Oy
Original Assignee
Zora Biosciences Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zora Biosciences Oy filed Critical Zora Biosciences Oy
Publication of CN106716127A publication Critical patent/CN106716127A/zh
Application granted granted Critical
Publication of CN106716127B publication Critical patent/CN106716127B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/64—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving ketones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7023—(Hyper)proliferation
    • G01N2800/7028—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
CN201580052938.0A 2014-10-02 2015-10-02 用于检测卵巢癌的方法 Active CN106716127B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20145855 2014-10-02
FI20145855 2014-10-02
PCT/FI2015/050654 WO2016051020A1 (en) 2014-10-02 2015-10-02 Methods for detecting ovarian cancer

Publications (2)

Publication Number Publication Date
CN106716127A CN106716127A (zh) 2017-05-24
CN106716127B true CN106716127B (zh) 2020-12-08

Family

ID=55629471

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580052938.0A Active CN106716127B (zh) 2014-10-02 2015-10-02 用于检测卵巢癌的方法

Country Status (10)

Country Link
US (1) US10534001B2 (https=)
EP (1) EP3201623B1 (https=)
JP (1) JP6892820B2 (https=)
KR (1) KR20170061704A (https=)
CN (1) CN106716127B (https=)
AU (1) AU2015326756A1 (https=)
BR (1) BR112017006593A2 (https=)
CA (1) CA2959832A1 (https=)
SG (1) SG11201701875YA (https=)
WO (1) WO2016051020A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351938A1 (en) * 2017-01-18 2018-07-25 BIOCRATES Life Sciences AG New biomarkers for assessing ovarian cancer
US20210405054A1 (en) 2017-07-05 2021-12-30 Zora Biosciences Oy Methods for detecting ovarian cancer
CN107656006A (zh) * 2017-09-08 2018-02-02 上海市东方医院 用于检测血清或者血浆中α‑羟基丁酸浓度的试剂盒和方法
CN108152430A (zh) * 2017-12-21 2018-06-12 上海中科新生命生物科技有限公司 基于prm检测的卵巢癌标志物检测试剂盒及检测方法
WO2020160108A1 (en) * 2019-01-30 2020-08-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Lipid biomarkers for cancer screening and monitoring
CN111430030A (zh) * 2020-04-17 2020-07-17 武汉大学 生物标志物在卵巢癌评估中的应用方法及系统
CN114544848B (zh) * 2020-11-25 2023-04-28 中国科学院大连化学物理研究所 一种用于诊断卵巢上皮癌的血清脂质标志物组合物及试剂盒和其与应用
EP4246146A1 (en) * 2022-03-14 2023-09-20 Fundació Institut Mar d'Investigacions Mèdiques (IMIM) Method for diagnosing cancer

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994141A (en) * 1996-05-30 1999-11-30 The Cleveland Clinic Foundation Method of detecting gynecological carcinomas
WO2009052186A1 (en) * 2007-10-15 2009-04-23 Georgia Tech Research Corporation Metabolomics-based identification of disease-causing agents
WO2009096903A1 (en) * 2008-01-28 2009-08-06 National University Of Singapore Lipid tumour profile
WO2012168561A1 (en) * 2011-06-10 2012-12-13 Teknologian Tutkimuskeskus Vtt Method of diagnosing on increased risk of alzheimer's disease
WO2013016700A1 (en) * 2011-07-27 2013-01-31 The Research Foundation Of State University Of New York Methods for generating predictive models for epithelial ovarian cancer and methods for identifying eoc

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054942A1 (en) * 2002-01-22 2005-03-10 Melker Richard J. System and method for therapeutic drug monitoring
US20030180953A1 (en) * 2000-12-29 2003-09-25 Elitra Pharmaceuticals, Inc. Gene disruption methodologies for drug target discovery
WO2003015436A1 (de) * 2001-08-10 2003-02-20 Siemens Aktiengesellschaft Verfahren zum schnellen und lokalen fehlerbeheben beim ausfall einzelner physikalischer verbindungen in gebündelten kommunikationsverbindungen und kommunikationssystem-vorrichtung zum durchführen des verfahrens
US20040180387A1 (en) * 2003-03-13 2004-09-16 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
US20050170441A1 (en) 2003-09-12 2005-08-04 Health Research, Inc. Early detection of cancer of specific type using 1HNMR metabonomics
US20120004854A1 (en) 2008-05-28 2012-01-05 Georgia Tech Research Corporation Metabolic biomarkers for ovarian cancer and methods of use thereof
JP4744618B2 (ja) * 2009-04-13 2011-08-10 シャープ株式会社 ガス成分検出装置
BRPI1016102A2 (pt) * 2009-04-15 2015-09-01 Sanford Burhnham Medical Res Inst Inibidores de proteínas anti-apoptótica baseados em naftaleno
US20120197539A1 (en) * 2009-10-09 2012-08-02 Carolyn Slupsky Methods for diagnosis, treatment and monitoring of patient health using metabolomics
US20110114511A1 (en) * 2009-11-17 2011-05-19 Sjong Angele Apparatus for detecting volatile organic compounds and related methods
GB201016139D0 (en) 2010-09-24 2010-11-10 Univ Leuven Kath Cancer phosholipidome

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994141A (en) * 1996-05-30 1999-11-30 The Cleveland Clinic Foundation Method of detecting gynecological carcinomas
WO2009052186A1 (en) * 2007-10-15 2009-04-23 Georgia Tech Research Corporation Metabolomics-based identification of disease-causing agents
WO2009096903A1 (en) * 2008-01-28 2009-08-06 National University Of Singapore Lipid tumour profile
WO2012168561A1 (en) * 2011-06-10 2012-12-13 Teknologian Tutkimuskeskus Vtt Method of diagnosing on increased risk of alzheimer's disease
WO2013016700A1 (en) * 2011-07-27 2013-01-31 The Research Foundation Of State University Of New York Methods for generating predictive models for epithelial ovarian cancer and methods for identifying eoc

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer biomarkers and mass spectrometry-based;Karol Jelonek et al.;《Clinicl lipidology》;20130201;第145页第1列第24-30行 *
Dtection of epithelial ovarian cancer using 1H-NMR-based metabonomics;Kunle Odunsi et al;《international journal of cancer,》;20040101;正文第5页第3段，附图1 *

Also Published As

Publication number Publication date
JP2017535756A (ja) 2017-11-30
US10534001B2 (en) 2020-01-14
KR20170061704A (ko) 2017-06-05
BR112017006593A2 (pt) 2017-12-19
CN106716127A (zh) 2017-05-24
EP3201623A4 (en) 2018-07-25
US20170285036A1 (en) 2017-10-05
EP3201623B1 (en) 2020-07-22
JP6892820B2 (ja) 2021-06-23
EP3201623A1 (en) 2017-08-09
AU2015326756A1 (en) 2017-05-11
SG11201701875YA (en) 2017-04-27
WO2016051020A1 (en) 2016-04-07
CA2959832A1 (en) 2016-04-07

Similar Documents

Publication Publication Date Title
CN106716127B (zh) 用于检测卵巢癌的方法
Liu et al. LC-MS-based plasma metabolomics and lipidomics analyses for differential diagnosis of bladder cancer and renal cell carcinoma
Hilvo et al. Accumulated metabolites of hydroxybutyric acid serve as diagnostic and prognostic biomarkers of ovarian high-grade serous carcinomas
US20180196074A1 (en) Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps
Chan et al. Metabonomic profiling of bladder cancer
JP2017533413A (ja) 乳癌を評価するためのバイオマーカー
WO2011151252A2 (en) Means and methods for diagnosing pancreatic cancer in a subject
JP2017504011A (ja) 代謝物質パネルに基づく被験体において膵臓癌を診断するための手段および方法
Li et al. Serum untargeted metabolomics reveal metabolic alteration of non‐small cell lung cancer and refine disease detection
Yan et al. A serum lipidomics study for the identification of specific biomarkers for endometrial polyps to distinguish them from endometrial cancer or hyperplasia
Zhang et al. A simplified and efficient extracellular vesicle-based proteomics strategy for early diagnosis of colorectal cancer
WO2011036117A1 (en) Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
Yumba-Mpanga et al. Metabolomic heterogeneity of urogenital tract cancers analyzed by complementary chromatographic techniques coupled with mass spectrometry
Buszewska-Forajta et al. Untargeted metabolomics study of three matrices: seminal fluid, urine, and serum to search the potential indicators of prostate cancer
Kałużna-Czaplińska et al. Current applications of chromatographic methods for diagnosis and identification of potential biomarkers in cancer
Devillier et al. Metabolomics in the diagnosis and pharmacotherapy of lung diseases
CN110749732B (zh) 诊断多发性骨髓瘤的血液代谢物标志物及应用
Recber et al. Optimization and normalization strategies for long term untargeted HILIC-LC-qTOF-MS based metabolomics analysis: Early diagnosis of breast cancer
Mitura et al. Fourier transform InfraRed spectra analyzed by multivariate and machine learning methods in determination spectroscopy marker of prostate cancer in dried serum
US20150285805A1 (en) Biomarkers of multiple myeloma development and progression
JP2010266386A (ja) 患者由来の代謝物を使用したがんの検査方法
Jirásko et al. Pola nski
CN105717205A (zh) 用于诊断稳定型心绞痛的代谢标志物
AU2024257583A1 (en) Method of diagnosis and treatment of pancreatic cancer
Rakhshan et al. Applications of mass spectroscopy in understanding cancer proteomics

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant